Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be limited, citing India's manufacturing cost advantage, US-based production facilities of several drugmakers and uncertainty over how and when the tariffs will be implemented.